InspireMD, Inc. — Director's Dealing 2023

May 16, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: InspireMD, Inc. (NSPR)
CIK: 0001433607
Period of Report: 2023-05-12

Reporting Person: Stuka Paul (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-05-12	Common Stock	P	175000	$1.6327	Acquired	248534	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-12	Series H Warrants to purchase Common Stock	$1.3827	P	87500	Acquired		Common Stock (87500)	Indirect
2023-05-12	Series I Warrants to purchase Common Stock	$1.3827	P	87500	Acquired		Common Stock (87500)	Indirect
2023-05-12	Series J Warrants to purchase Common Stock	$1.3827	P	87500	Acquired		Common Stock (87500)	Indirect
2023-05-12	Series K Warrants to purchase Common Stock	$1.3827	P	87500	Acquired		Common Stock (87500)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	42320	Direct

Footnotes

F1: The shares of common stock reported in this row represent shares of restricted stock that were acquired in a private placement transaction on May 12, 2023 pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Private Placement").

F2: The purchase price per share of common stock and associated Series H Warrants, Series I Warrants, Series J Warrants and Series K Warrants in the Private Placement was $1.6327.

F3: These securities are held by Osiris Investment Partners, L.P. ("Osiris"). The Reporting Person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris. In such capacity, the Reporting Person may be deemed to beneficially own the reported securities. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes.

F4: The aggregate number of warrants reported in this row consists of 87,500 Series H Warrants that were acquired in the Private Placement.

F5: The Series H Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's public release of primary and secondary end points related to one year follow up study results from the Company's C-Guardians pivotal trial.

F6: The aggregate number of warrants reported in this row consists of 87,500 Series I Warrants that were acquired in the Private Placement.

F7: The Series I Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of Premarket Approval (PMA) from the Food and Drug Administration ("FDA") for the CGuard Prime Carotid Stent System (135 cm).

F8: The aggregate number of warrants reported in this row consists of 87,500 Series J Warrants that were acquired in the Private Placement.

F9: The Series J Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the Company's announcement of receipt of FDA approval for the SwitchGuard transcarotid system and CGuard Prime 80 cm.

F10: The aggregate number of warrants reported in this row consists of 87,500 Series K Warrants that were acquired in the Private Placement.

F11: The Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of the CGuard Carotid Stent System in the United States begin.